Federal Register / Vol. 87, No. 83 / Friday, April 29, 2022 / Notices 25499 

and Users to ensure it does not result in 

an activity prohibited by any U.S. 

export regulations, or other restriction. 

Before taking further action, to ensure 

full compliance with all the terms and 

conditions of the restrictions placed on 

the parties on this list, the Provider 

must check the official publication of 

restricted parties in the Federal 

Register. They should also check the 

official lists of restricted parties 

maintained on the websites of the 

Departments of Commerce, State, and 

the Treasury. 

Following up with the U.S. 

Government in Cases Where Malintent 

is Suspected by Providers or Third-Party 

Vendors: If sequence or Customer 

screening raises concerns that are not 

alleviated through follow-up screening, 

Providers and Third-Party Vendors are 

encouraged to contact the nearest FBI 

Field Office Weapons of Mass 

Destruction (WMD) Coordinator. 

Institutions are encouraged to work with 

their Principal Users and End Users to 

help them understand that only 

individuals with legitimate, bona fide, 

and peaceful need should obtain 

oligonucleotides containing SOCs. 

Records Retention: The Revised 

Guidance recommends that Providers, 

Third-Party Vendors, and 

Manufacturers: 

• Using responsible business 

practices, retain records of Customer 

orders for at least 8 years. 

• Archive the following information: 

Customer information (point-of contact 

name, organization, address, email, and 

phone number), order sequence 

information (nucleotide sequences 

ordered, vector used), and order 

information (date placed and shipped, 

shipping address, receiver name). 

• Develop and document protocols 

for sequence screening and for 

determining whether a sequence hit 

qualifies as a SOC and maintain records 

of these protocols—even if no longer 

current—for at least 8 years. 

• Retain screening documentation of 

all hits for at least 8 years, even if the 

order was deemed acceptable. 

• Retain records of any follow-up 

screening, even if the order was 

ultimately filled, for at least 8 years. 

Periodic Review, Evaluation, and 

Improvement of This Guidance: This 

Revised Guidance is addressing 

biosecurity risks that have emerged in a 

dynamic and rapidly developing 

technological landscape. It is likely that 

new risks will emerge and that new 

technological approaches will also 

appear to address biosecurity risks. As 

such, this Revised Guidance encourages 

the further development of mechanisms 

to detect SOCs and screening strategies 

for sequences that contribute to 

pathogenicity and toxicity. For instance, 

strategies may be used by malicious 

Customers to obfuscate SOCs, including 

engineering pathogenic or toxic proteins 

with completely novel sequences. In 

such cases, synthetic oligonucleotide 

orders may contain 50 bp windows that 

are not a match to any known sequence. 

Although there are likely several 

legitimate explanations for orders of 

sequences with no matches in nature 

(e.g., oligonucleotides to populate 

microarrays or to store digital 

information), in such cases, it may be 

possible to use predictive bioinformatic 

algorithms to screen sequences that are 

not a match to any known sequences to 

determine if they could produce 

proteins that are structurally and 

functionally identical to SOCs. This 

Revised Guidance encourages Providers 

to continue to develop these methods to 

best ensure the safety of the synthetic 

oligonucleotide research enterprise. 

Likewise, while there is not a 

comprehensive and curated database 

available presently for sequences that 

may contribute to pathogenicity or 

toxicity by enabling the circumvention 

of medical countermeasures (MCM), 

such as therapeutics or vaccines, such 

information may become increasingly 

available in coming years. This Revised 

Guidance encourages the identification 

of such MCM-evasive sequences and 

may revisit the definition of SOCs in the 

future, given advances in this field. 

Dawn O’Connell, 

Assistant Secretary for Preparedness and 

Response. 

[FR Doc. 2022–09210 Filed 4–28–22; 8:45 am] 

BILLING CODE 4150–37–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Applications (P01 Clinical 

Trial Not Allowed). 

Date: May 31, 2022. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G41, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Tara Capece, Ph.D., MPH, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G41, Rockville, MD 

20852, 240–191–4281, capecet2@

niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: April 25, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–09193 Filed 4–28–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

Animal Genomics Program. 

Date: May 25, 2022. 

Time: 12:00 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 


lotter on DSK11XQN23PROD with NOTICES1
25500 Federal Register / Vol. 87, No. 83 / Friday, April 29, 2022 / Notices 

Contact Person: Ipolia R. Ramadan, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, 301 North Stonestreet 

Avenue, MSC 6021, Bethesda, MD 20892, 

(301) 827–4471, ramadanir@mail.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; HEAL 

Initiative: Recovery Support Services for 

Individuals Treated with Medications for 

Opioid Use Disorder. 

Date: June 6, 2022. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Soyoun Cho, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

National Institute on Drug Abuse, NIH, 301 

North Stonestreet Avenue, MSC 6021, 

Bethesda, MD 20892, (301) 594–9460, 

Soyoun.cho@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: April 25, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–09189 Filed 4–28–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Applications (P01 Clinical 

Trial Not Allowed). 

Date: June 6, 2022. 

Time: 10:00 a.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G41, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Tara Capece, Ph.D., MPH, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G41, Rockville, MD 

20852, 240–191–4281 capecet2@

niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: April 25, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–09192 Filed 4–28–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

Interpersonal Strategies for Suicide 

Prevention. 

Date: May 20, 2022. 

Time: 10:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Nicholas Gaiano, Ph.D., 

Review Branch Chief, Division of Extramural 

Activities, National Institute of Mental 

Health, National Institutes of Health, 

Neuroscience Center/Room 6150/MSC 9606, 

6001 Executive Boulevard, Bethesda, MD 

20892–9606, 301–443–2742, nick.gaiano@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants, National Institutes of Health, HHS) 

Dated: April 26, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–09225 Filed 4–28–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–5: NCI 

Clinical and Translational Cancer Research. 

Date: May 26, 2022. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W108, Rockville, Maryland 20850 (Virtual 

Meeting). 

Contact Person: Clifford W. Schweinfest, 

Ph.D., Scientific Review Officer, Special 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W108, 

Rockville, Maryland 20850, 240–276–6343, 

schweinfestcw@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; U01 

CTD2—Cancer Target Discovery and 

Development Network (PAR21–274). 

Date: May 26, 2022. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W106, Rockville, Maryland 20850 (Virtual 

Meeting). 

Contact Person: Eduardo Emilio Chufan, 

Ph.D., Scientific Review Officer, Research 


lotter on DSK11XQN23PROD with NOTICES1